Decreased plasma growth hormone (GH) levels in acromegalics following CB 154(2-Br-alpha ergocryptine) administration.

Suppr

超能文献

作者信息

Liuzzi A, Chiodini P G, Botalla L, Cremascoli G, Müller E E, Silvestrini F

出版信息

J Clin Endocrinol Metab. 1974 May;38(5):910-2. doi: 10.1210/jcem-38-5-910.

DOI:10.1210/jcem-38-5-910

PMID:4823928

Abstract

摘要

相似文献

Decreased plasma growth hormone (GH) levels in acromegalics following CB 154(2-Br-alpha ergocryptine) administration.

J Clin Endocrinol Metab. 1974 May;38(5):910-2. doi: 10.1210/jcem-38-5-910.

Changes in plasma growth hormone levels in normal and acromegalic subjects following administration of 2-bromo-alpha-ergocryptine.

J Clin Endocrinol Metab. 1975 Mar;40(3):363-6. doi: 10.1210/jcem-40-3-363.

Stable reduction of plasma growth hormone (hGH) levels during chronic administration of 2-Br-alpha-ergocryptine (CB-154) in acromegalic patients.

J Clin Endocrinol Metab. 1975 Apr;40(4):705-8. doi: 10.1210/jcem-40-4-705.

Unaltered plasma GH levels in acromegalics and normal men and women after administration of (Pyro)Glu-Ser-Gly-NH2, a proposed GH-releasing hormone.

J Clin Endocrinol Metab. 1974 Jun;38(6):1134-6. doi: 10.1210/jcem-38-6-1134.

J Clin Endocrinol Metab. 1977 Jan;44(1):78-84. doi: 10.1210/jcem-44-1-78.

Growth hormone (GH)-releasing activity of TRH and GH-lowering effect of dopaminergic drugs in acromegaly: homogeneity in the two responses.

J Clin Endocrinol Metab. 1974 Nov;39(5):871-6. doi: 10.1210/jcem-39-5-871.

Effects of sumatriptan on growth hormone releasing hormone-stimulated growth hormone secretion in acromegaly.

Recenti Prog Med. 1997 Jun;88(6):264-8.

Pulsatile growth hormone secretion in patients with acromegaly and normal men: the effects of growth hormone-releasing hormone infusion.

J Clin Endocrinol Metab. 1990 Sep;71(3):585-90. doi: 10.1210/jcem-71-3-585.

Abnormal control of growth hormone secretion by opiate systems in acromegalic patients: a study with naloxone and 2-Br-alpha-ergocryptine (CB 154).

Med Biol. 1981 Feb;59(1):58-63.

[125I]hGH metabolism in acromegaly: effects of chronic treatment with 2-Br-alpha-ergocryptine.

J Clin Endocrinol Metab. 1978 Jul;47(1):110-8. doi: 10.1210/jcem-47-1-110.

引用本文的文献

Pegvisomant and cabergoline combination therapy in acromegaly.

Pituitary. 2013 Mar;16(1):101-8. doi: 10.1007/s11102-012-0382-z.

Pharmacological therapy for acromegaly: a critical review.

Drugs. 2004;64(16):1817-38. doi: 10.2165/00003495-200464160-00007.

Somatostatin analogs in medical treatment of acromegaly.

Endocrine. 2003 Apr;20(3):271-8. doi: 10.1385/ENDO:20:3:271.

Medical management of growth hormone-secreting pituitary adenomas.

Pituitary. 2002;5(2):67-76. doi: 10.1023/a:1022356313153.

Acromegaly: historical perspectives and current therapy.

J Neurooncol. 2001 Sep;54(2):129-37. doi: 10.1023/a:1012949214960.

Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients.

J Endocrinol Invest. 1997 Oct;20(9):537-46. doi: 10.1007/BF03348016.

Bromocriptine treatment over 12 years in acromegaly: effect on glucose tolerance and insulin secretion.

Clin Investig. 1993 May;71(5):372-8. doi: 10.1007/BF00186626.

Long-term treatment of acromegalic patients with repeatable parenteral depot-bromocriptine.

Clin Investig. 1993 Jul;71(7):547-51. doi: 10.1007/BF00208479.

Acromegaly. Recognition and treatment.

Drugs. 1994 Mar;47(3):425-45. doi: 10.2165/00003495-199447030-00004.

Bromocriptine therapy in acromegaly. A long-term review of 35 cases.

Postgrad Med J. 1981 Apr;57(666):210-6. doi: 10.1136/pgmj.57.666.210.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验